Depigoid

Phase 3Small molecule

Novartis

Depigoid is one of 71 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Allergic AsthmaActive, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

Allergic AsthmaPhase 3

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Sudafed

KKenvue Brands

Phase 3

3 3

Flovent

PParatek Pharmaceuticals Inc

Phase 3

2 4

Rayos

RRoxane Laboratories

Phase 3

1 5

Kenalog

BBassett Healthcare

Phase 3

1 6

Active Comparator

Moderna

Phase 3

1 7

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 8

Allegra-D

Pfizer

Phase 3

3 9

Asmanex

Depigoid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Asthma1 trial

Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis

Completed· Novartis logo

Novartis·Phase 3·NCT00396409·128 enrolled

Allergic Rhinitis1 trial

Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma

Terminated·LLaboratorios Leti, S.L.·Phase 2·NCT01591343·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Depigoid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Depigoid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Depigoid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Depigoid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Asthma1 trial

Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News